Stifel downgraded Third Harmonic Bio (THRD) to Hold from Buy with a price target of $5, down from $23, following the company’s decision to undergo a strategic review following Phase 1 data from THB335 that had “some key safety questions at the high end of the dose range.” Stifel also noted that, concurrent with the review, the company was discontinuing all non-THB335 R&D and cutting its workforce by 50%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THRD:
- Third Harmonic Bio reports FY24 EPS ($1.09) vs. (78c) last year
- Third Harmonic Bio reports THB335 program next steps
- Third Harmonic Bio initiates process to identify opportunities to maximize value
- THRD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Third Harmonic Bio Advances THB335 for Inflammatory Diseases